Isomorphic Labs raises $5B Series C six months after a $2.1B round
Greenoaks and Sequoia Capital co-led the round for the London AI drug designer, with Andreessen Horowitz joining and Alphabet investing again. Isomorphic says the money will help push its first programs toward clinical trials.

- Amount
- $5B
- Type
- Series C
- Company
- Isomorphic Labs
- Led by
- Greenoaks, Sequoia Capital
- Sector
- Biotech
- Announced
- Nov. 17, 2026
Isomorphic Labs says its first drug programs are still on the way to clinical trials. Investors have now committed $5 billion more to get them there. The London company, which designs medicines with artificial intelligence, said Nov. 17 that it raised the money in an oversubscribed Series C co-led by Greenoaks and Sequoia Capital.
Andreessen Horowitz and several unnamed new investors joined the round, and Alphabet made what Isomorphic called a continued significant investment. Every existing investor took part as well: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose a valuation.
Why it matters: The round comes six months after Isomorphic raised $2.1 billion in a Series B led by Thrive Capital, UKTN reported in May. The new round is more than twice that size, and Isomorphic said it will use the money both to push its first programs toward clinical trials and to build the research and development infrastructure around them.
What Isomorphic is building
The company's core asset is a drug design engine it calls IsoDDE, which it describes as a set of foundational simulation models that work across therapeutic areas and drug types. Isomorphic said it pairs those models with its own AI agents that reason over complex biological systems, and that the work is feeding a pipeline of candidates in several modalities.
According to the company, its own oncology and immunology programs, along with partnered ones, are producing positive preclinical results. It did not name the programs, partners or the timing of a first trial.
Demis Hassabis, the founder and chief executive, said the round will help with "driving our first therapeutic programs towards clinical trials." Isomorphic was founded in 2021 and is led by Hassabis and Max Jaderberg, its president. It is based in London, with offices in Cambridge, Mass., and Lausanne, Switzerland.
Neil Mehta, founder and managing partner of Greenoaks, framed the investment around the problem. "Discovering and developing new medicines is an optimization challenge of almost infinite scale," he said.
Where the money goes
Isomorphic said it will keep developing IsoDDE, build more advanced models of new biology, and create a partner network aimed at understanding the mechanisms of disease. It also plans to build what it called global infrastructure for AI-led bioengineering, and to fund translational and clinical development capacity as candidates head toward trials.
The funding history
In the May round, existing backers Alphabet and GV were joined by new investors MGX, Temasek and CapitalG, and the U.K.'s sovereign AI fund also contributed, according to UKTN. The outlet reported that Isomorphic had raised £462.3 million in a round announced in April 2025.
What to watch
The company has not said when its first candidate will enter human testing, which program it will be, or whether it will be an internal or partnered asset. Those are the disclosures that will show whether the new capital is turning into clinical work.



